Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11438341 | 0.87 | NPC1 (0.89) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL4883318 | 0.81 | NPC1 (1.00) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12171414 | 0.80 | NPC1 (0.96) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12171885 | 0.80 | NPC1 (0.77) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12171408 | 0.79 | NPC1 (0.74) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL70030 | 0.79 | NPC1 (0.69) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12171934 | 0.79 | NPC1 (0.74) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12798171 | 0.79 | NPC1 (0.74) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12170932 | 0.79 | NPC1 (0.74) | NPC1RAB9AKMT2ANR1H4MYC | |
| SCHEMBL12171897 | 0.79 | NPC1 (0.74) | NPC1RAB9AKMT2ANR1H4MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000964-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4279502-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED THEREFROM | AJINOMOTO CO., INC. (JP) | 2023-11-22 | — | — | EP | disclosed |
| CN-116761819-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-09-15 | — | — | CN | disclosed |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| WO-2022154127-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED THEREFROM | 味の素株式会社 | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000964-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | SSB, CTH, SCLY | NPC1 3657/4885RAB9A 331/4885KMT2A 991/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | NPC1 561/4885RAB9A 1179/4885KMT2A 1603/4885 |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | NPC1 3155/4885RAB9A 1134/4885KMT2A 650/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | NPC1 3878/4885RAB9A 977/4885KMT2A 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.